How Oncotarget is Making Scientific Research Findings Accessible to Researchers and Medical Practitioners

A recent article posted on Research Gate by Oncotarget suggests that aberrant chromobox (CBX6) protein induces tumor progression. The article also pointed out that CBX6 is found in several human malignancies. A study revealed that CBX6 protein is related to large tumor sizes. Patients with high amounts of this protein were likely to develop tumors around different parts of their bodies. Consequently, those with low amounts of this protein were less likely to develop tumors.

CBX6 protein also promotes the growth of HCC cells. The protein serves as a crucial biomarker for HCC. It can also be used in the treatment of tumor-related diseases as Oncotarget researchers explained in the article. Multivariate analyses depicted that HCC patients responded unfavorably to increased CBX6 expression. Follow Oncotarget on Twitter.

Oncotarget’s Efforts to Release Two Issues Every Week

As a multidisciplinary biomedical journal, Oncotarget’s publications are available on PubMed, Scopus, BIOSIS Previews, and Science Citation. Oncotarget partnered with the National Library of Medicine to release its entire issues to PubMed. The biomedical journal works in conjunction with scientific archives and indexes. These efforts are aimed at making scientific results easily available to researchers and medical practitioners. The online journal also announced to its readers that it would be uploading two articles every week on PubMed.

Read more:

Oncotarget began availing peer-reviewed and open access articles to researchers and medical practitioners in 2010. These publications cover topics on aging, pathology, oncology, immunology, and microbiology. They also cover topics on chromosomes and autophagy. Oncotarget has over 324 issues and eight volumes in its catalog. Its publications adhere to the regulations of published works enacted by the Committee on Publication Ethics. They also have a direct object identifier (DOI).

A statement released by Oncotarget’s office of external and legal affairs stated that Oncotarget’s issues address the 21st-century challenges. The statement also mentioned that Oncotarget is on a mission to be renowned for its informative biomedical research findings. The journal continues to be a resource to researchers who have a shared vision of changing the medical field. Under the management of prominent researchers like Mikhail Blagosklonny, Oncotarget helps all medical practitioners and research enthusiasts to contribute to the advances in science. Visit: